Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1995 1
1999 1
2003 1
2004 2
2005 3
2006 5
2007 11
2008 6
2009 5
2010 6
2011 8
2012 10
2013 19
2014 14
2015 17
2016 14
2017 18
2018 29
2019 39
2020 48
2021 42
2022 56
2023 62
2024 52

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

425 results

Results by year

Filters applied: . Clear all
Page 1
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
D'Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, Krueger K, Laskowski J, Li X, Lissoos T, Milata J, Morris N, Arora V, Milch C, Sandborn W, Sands BE; LUCENT Study Group. D'Haens G, et al. N Engl J Med. 2023 Jun 29;388(26):2444-2455. doi: 10.1056/NEJMoa2207940. N Engl J Med. 2023. PMID: 37379135 Clinical Trial.
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.
Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, D'Haens G, Ferrante M, Schreiber S, Atreya R, Danese S, Lindsay JO, Bossuyt P, Siegmund B, Irving PM, Panaccione R, Cao Q, Neimark E, Wallace K, Anschutz T, Kligys K, Duan WR, Pivorunas V, Huang X, Berg S, Shu L, Dubinsky M; SEQUENCE Study Group. Peyrin-Biroulet L, et al. N Engl J Med. 2024 Jul 18;391(3):213-223. doi: 10.1056/NEJMoa2314585. N Engl J Med. 2024. PMID: 39018531 Clinical Trial.
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
D'Haens G, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV Jr, Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, Ferrante M. D'Haens G, et al. Among authors: ran z. Lancet. 2022 May 28;399(10340):2015-2030. doi: 10.1016/S0140-6736(22)00467-6. Lancet. 2022. PMID: 35644154 Clinical Trial.
Advances in exosome biomarkers for cervical cancer.
Ran Z, Wu S, Ma Z, Chen X, Liu J, Yang J. Ran Z, et al. Cancer Med. 2022 Dec;11(24):4966-4978. doi: 10.1002/cam4.4828. Epub 2022 May 16. Cancer Med. 2022. PMID: 35578572 Free PMC article. Review.
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV Jr, Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, D'Haens G. Ferrante M, et al. Among authors: ran z. Lancet. 2022 May 28;399(10340):2031-2046. doi: 10.1016/S0140-6736(22)00466-4. Lancet. 2022. PMID: 35644155 Clinical Trial.
Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials.
Louis E, Schreiber S, Panaccione R, Bossuyt P, Biedermann L, Colombel JF, Parkes G, Peyrin-Biroulet L, D'Haens G, Hisamatsu T, Siegmund B, Wu K, Boland BS, Melmed GY, Armuzzi A, Levine P, Kalabic J, Chen S, Cheng L, Shu L, Duan WR, Pivorunas V, Sanchez Gonzalez Y, D'Cunha R, Neimark E, Wallace K, Atreya R, Ferrante M, Loftus EV Jr; INSPIRE and COMMAND Study Group. Louis E, et al. JAMA. 2024 Sep 17;332(11):881-897. doi: 10.1001/jama.2024.12414. JAMA. 2024. PMID: 39037800 Clinical Trial.
Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus.
Ananthakrishnan AN, Kaplan GG, Bernstein CN, Burke KE, Lochhead PJ, Sasson AN, Agrawal M, Tiong JHT, Steinberg J, Kruis W, Steinwurz F, Ahuja V, Ng SC, Rubin DT, Colombel JF, Gearry R; International Organization for Study of Inflammatory Bowel Diseases. Ananthakrishnan AN, et al. Lancet Gastroenterol Hepatol. 2022 Jul;7(7):666-678. doi: 10.1016/S2468-1253(22)00021-8. Epub 2022 Apr 27. Lancet Gastroenterol Hepatol. 2022. PMID: 35487235 Review.
Effect of Induction Therapy With Olamkicept vs Placebo on Clinical Response in Patients With Active Ulcerative Colitis: A Randomized Clinical Trial.
Zhang S, Chen B, Wang B, Chen H, Li Y, Cao Q, Zhong J, Shieh MJ, Ran Z, Tang T, Yang M, Xu B, Wang Q, Liu Y, Ma L, Wang X, Zhang N, Zhang S, Guo W, Huang L, Schreiber S, Chen M. Zhang S, et al. Among authors: ran z. JAMA. 2023 Mar 7;329(9):725-734. doi: 10.1001/jama.2023.1084. JAMA. 2023. PMID: 36881032 Free PMC article. Clinical Trial.
Epithelial-mesenchymal transition in Crohn's disease.
Jiang H, Shen J, Ran Z. Jiang H, et al. Among authors: ran z. Mucosal Immunol. 2018 Mar;11(2):294-303. doi: 10.1038/mi.2017.107. Epub 2017 Dec 20. Mucosal Immunol. 2018. PMID: 29346350 Free article. Review.
425 results